^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19 inhibitor

    Related drugs:
    21h
    A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Imugene Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Blincyto (blinatumomab) • hydroxyurea • VAXinia (CF33-hNIS) • onCARlytics (CF33-CD19)
    22h
    ELiPSE-1: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (clinicaltrials.gov)
    P1, N=28, Terminated, Century Therapeutics, Inc. | Trial completion date: Aug 2027 --> Jul 2025 | Active, not recruiting --> Terminated; Strategic decision
    Trial completion date • Trial termination
    |
    CD19 positive
    |
    CNTY-101
    1d
    ASSURO: Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    surovatamig (AZD0486)
    1d
    A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=104, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    1d
    A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL (clinicaltrials.gov)
    P1/2, N=281, Recruiting, Amgen | Trial primary completion date: Jul 2027 --> Nov 2027
    Trial primary completion date • Minimal residual disease
    3d
    Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    3d
    A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ
    |
    Revuforj (revumenib)
    3d
    A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM) (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Xencor, Inc.
    New P1 trial • First-in-human
    |
    plamotamab (XmAb13676)
    4d
    Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL (clinicaltrials.gov)
    P2, N=41, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • lenalidomide • Monjuvi (tafasitamab-cxix)
    4d
    Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity. (PubMed, Front Med (Lausanne))
    Blinatumomab combined with low-dose chemotherapy and TKIs demonstrated a trend toward improved MRD negativity, lower relapse rates, and reduced hematologic toxicity compared to conventional chemotherapy. These findings support further investigation in larger trials to confirm clinical benefit.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Blincyto (blinatumomab)
    9d
    Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
    Bispecific antibodies such as blinatumomab (anti-CD19), antibody-drug conjugates like inotuzumab ozogamicin (anti-CD22), and monoclonal antibodies such as daratumumab (anti-CD38) have demonstrated efficacy in relapsed or refractory disease with improved safety profiles. The integration of targeted and immune-based therapies into conventional regimens represents a decisive step toward precision medicine, aiming to enhance survival outcomes while reducing treatment-related toxicity and improving quality of life in ALL children. This review aims to provide a comprehensive overview of the current understanding of ALL pathobiology and therapeutic approaches, with particular emphasis on the expanding role of immunotherapeutic strategies in pediatric disease.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Darzalex (daratumumab)
    10d
    Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (clinicaltrials.gov)
    P2, N=56, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Monjuvi (tafasitamab-cxix)